MELLIsim company aims to develop and commercialising its new and revolutionary MELLIsense solution to address the huge unmet needs of Type 2 Diabetic (T2D) patients.
Since 2015, project team has been working closely with ITODYS, one of the best-in class research laboratories in electrochemical biosensors, to develop an innovative sensing solution specifically designed for Type 2 Diabetic patients.
By the end of 2019, after four years of technology maturation with the support of patient associations and renowned hospital specialists in France, Switzerland, England and Canada, MELLIsim has been created with the mission to deliver this effective solution.
The MELLIsim team is ready and highly motivated to bring on the market, by 2023, MELLIsense, a disruptive solution that is expected by patients and healthcare professionals.
MELLIsense aims at radically changing and correcting the current status of poorly controlled Type 2 Diabetic patients. It is one of the most ground-breaking changes in the last 20 years for these patients with huge medical and societal impacts. In a market dominated by US companies (Abbott, Dexcom, Medtronic), MELLIsim aims to become one independent European champion in diabetes care.
Our goal is to have our solution largely deployed among the 7.6 million first targeted patients in Europe, the US and Canada. To achieve this, we are setting up partnerships to distribute our solutions worldwide.